51. Scleroderma Clinical trials / Disease details

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

diseases per page:

Showing 1 to 10 of 525 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04986605 (ClinicalTrials.gov)	December 1, 2023	1/6/2021	Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis	The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis	Diffuse Cutaneous Systemic Sclerosis	Device: Extracorporeal Photopheresis (ECP);Drug: UVADEX	Lawson Health Research Institute	Mallinckrodt	Not yet recruiting	18 Years	N/A	All	15	Phase 2	Canada
2	NCT05149768 (ClinicalTrials.gov)	September 1, 2023	24/11/2021	Open Label Extension Study of Brentuximab Vedotin in Early dcSSc	An Open Label Extension Study of Brentuximab Vedotin Treatment in Active Diffuse Cutaneous Systemic ...	Diffuse Cutaneous Systemic Sclerosis	Drug: Brentuximab vedotin	Lawson Health Research Institute	Seagen Inc.	Not yet recruiting	18 Years	N/A	All	10	Phase 2	NULL
3	NCT05029336 (ClinicalTrials.gov)	September 2023	24/8/2021	Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases	Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Au ...	Systemic Lupus Erythematosus;Systemic Sclerosis	Biological: Depletion of CD3/CD19 in an autologous stem cell transplant	Stephan Grupp MD PhD	NULL	Recruiting	8 Years	25 Years	All	20	Phase 2	United States
4	NCT04948554 (ClinicalTrials.gov)	March 10, 2023	4/6/2021	A Study of MK-2225 / ACE-1334 in Participants With Systemic SclerosisWith and Without Interstitial L ...	A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate t ...	Systemic Sclerosis With and Without Interstitial Lung Disease	Biological: MK-2225;Biological: Placebo	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Recruiting	18 Years	N/A	All	48	Phase 1	United States;Canada
5	NCT04789850 (ClinicalTrials.gov)	February 2, 2023	10/2/2021	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Control ...	Systemic Sclerosis	Drug: Itacitinib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	N/A	All	74	Phase 2	France
6	EUCTR2022-001484-27-NL (EUCTR)	24/01/2023	29/10/2022	Basta 2	B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic SclerosisTissues ...	Systemic SclerosisSjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - I ...	Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam Product Code: IND 127861 INN or Proposed INN: [89Zr]Zr ...	radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Netherlands
7	NCT05462522 (ClinicalTrials.gov)	January 16, 2023	14/7/2022	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With ...	A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, ...	Systemic Sclerosis	Drug: RO7303509;Drug: Placebo	Genentech, Inc.	NULL	Recruiting	18 Years	75 Years	All	100	Phase 1	United States;Belgium;France;Israel;Poland;Puerto Rico;Spain
8	NCT04356287 (ClinicalTrials.gov)	January 5, 2023	15/4/2020	Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis	Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in System ...	Sclerosis, Systemic;Mesenchymal Stem Cells	Biological: UCMSC;Other: Placebo	Marie Hudson, MD	Medical University of South Carolina;McGill University Health Centre/Research Institute of the McGil ...	Recruiting	18 Years	N/A	All	18	Phase 1/Phase 2	Canada
9	EUCTR2021-006271-42-GR (EUCTR)	04/01/2023	02/11/2022	A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffus ...	A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-8 ...	Diffuse Cutaneous Systemic Sclerosis MedDRA version: 21.0;Level: LLT;Classification code 10042953;Te ...	Product Code: HZN-825 INN or Proposed INN: HZN-825	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 2	Portugal;United States;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Mexico;Ar ...
10	NCT03800017 (ClinicalTrials.gov)	January 1, 2023	21/11/2018	Skeletal Muscle Function in Interstitial Lung Disease	Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interst ...	Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Non ...	Biological: Hyperoxia	University of British Columbia	NULL	Not yet recruiting	40 Years	80 Years	All	40	N/A	NULL

First Previous1 2 3 4 5…53Next Last